Different measures for auditory hallucinations in populations with psychosis. The Validation of the Spanish versions of the Auditory Vocal Hallucination Rating Scale (AVHRS) and the Positive and Useful Voices Inquiry (PUVI)
Por:
Lorente-Rovira E., Grasa E., Ochoa S., Corripio I., Peláez T., López-Carrilero R., Gutiérrez-Gea Á., Morano-Guillén M., Villagrán J.M., Bartels-Velthuis A.A., Jenner J.A., Sanjuán J.
Publicada:
1 ene 2022
Ahead of Print:
1 ene 2020
Resumen:
Introduction: An updated summary of the most used instruments assessing auditory hallucinations in population with psychosis, allows us to underline the scarceness and need of Spanish versions of important instruments. The aim of the study is to examine the psychometric characteristics of two different and complementary instruments for assessing auditory hallucinations, the Spanish version of the Auditory Vocal Hallucination Scale (AVHRS) and the Spanish version of the Positive and Useful Voices Inquiry (PUVI). Materials and methods: A sample of 68 patients from four different centres, with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder presenting with auditory hallucinations were included. Apart from the AVHRS and the PUVI, the Psychotic Symptom Rating Scales-Auditory Hallucinations subscale (PSYRATS-AH) and the Positive and Negative Syndrome Scale (PANSS) were also administered to all patients, plus an acceptability questionnaire. Results: The Spanish version of the AVHRS showed a good internal consistency, a moderate to high inter-rater reliability, a medium to moderate test–retest reliability, and a good convergent and discriminant validity. The Spanish version of the PUVI showed a good internal consistency and a heterogeneous, but in general moderate, test–retest reliability. Conclusions: The Spanish versions of the AVHRS and the PUVI have good psychometric properties and are well accepted among patients. © 2020 SEP y SEPB
Filiaciones:
Lorente-Rovira E.:
Hospital Clínico, Valencia, Spain
INCLIVA, Valencia, Spain
CIBERSAM, Madrid, Spain
Grasa E.:
CIBERSAM, Madrid, Spain
Department of Psychiatry, Biomedical Research Institute Sant Pau (IIB-SANT PAU, Hospital Sant Pau, Barcelona, Spain
Universitat Autònoma de Barcelona (UAB), Spain
Ochoa S.:
CIBERSAM, Madrid, Spain
Parc Sanitari Sant Joan de Déu, Barcelona, Spain
Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Corripio I.:
CIBERSAM, Madrid, Spain
Department of Psychiatry, Biomedical Research Institute Sant Pau (IIB-SANT PAU, Hospital Sant Pau, Barcelona, Spain
Universitat Autònoma de Barcelona (UAB), Spain
Peláez T.:
CIBERSAM, Madrid, Spain
Parc Sanitari Sant Joan de Déu, Barcelona, Spain
López-Carrilero R.:
CIBERSAM, Madrid, Spain
Parc Sanitari Sant Joan de Déu, Barcelona, Spain
Gutiérrez-Gea Á.:
Hospital Jerez de la Frontera, Servicio Andaluz de Salud, Cádiz, Spain
Morano-Guillén M.:
Hospital Jerez de la Frontera, Servicio Andaluz de Salud, Cádiz, Spain
Villagrán J.M.:
Hospital Jerez de la Frontera, Servicio Andaluz de Salud, Cádiz, Spain
Bartels-Velthuis A.A.:
University of Groningen, Netherlands
University Medical Center Groningen, University Center for Psychiatry, Groningen, Netherlands
Jenner J.A.:
Jenner Consult, Haren, the Netherlands Groningen, Netherlands
Sanjuán J.:
Hospital Clínico, Valencia, Spain
INCLIVA, Valencia, Spain
CIBERSAM, Madrid, Spain
Faculty of Medicine, Valencia, Spain
|